Abstract:Mice recovered from influenza A virus infection have been shown to be cross-protected against challenge infection with either drift viruses within a subtype (subtype-specific immunity) or different subtype viruses (heterosubtypic immunity). The mechanisms of broad-spectrum of cross-protection could be explained as follows. (i) Pre-existing S-IgA and IgG antibodies (Abs) induced by infection are involved in the elimination of challenge viruses by forming virus-Ig complexes shortly after re-infection. Due to their polymeric nature, the S-IgA Abs, existing more abundant on the mucosa than are IgG Abs, are strongly cross-reactive with challenge viruses, whereas the IgG Abs are weakly cross-reactive with challenge viruses, due to their monomeric nature. The specificity of Abs is directed mainly at hemagglutinin and neuraminidase. (ii) CD8+ memory T cells induced by infection are involved in the elimination of challenge viruses by the accelerated killing of host cells infected with different subtype viruses from day 3 onwards after re-infection. The specificity of memory T cells is directed against viral internal proteins. (iii) The accelerated IgA and IgG Ab responses, produced by B memory cells after a challenge, are also involved in cross-protection from day 4 onwards after re-infection. (iv) In the epithelial cells of infected mice, dimeric IgA that is trafficked through the epithelial cells can contribute to the prevention of viral assembly by binding to newly synthesized viral proteins. Natural infection is well known to be superior to parenteral inactivated vaccines in inducing the broad-spectrum cross-protection. To improve the efficacy of current inactivated vaccines, many trials have been conducted to mimic natural infection, including intranasal or epidermal administration of inactivated vaccine with or without an adjuvant; such studies are still ongoing. In the near future, some of these trials may provide new, safer and more effective broad-spectrum vaccines than those currently available.

Induction of heterosubtypic immunity to influenza virus by intranasal immunization

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice

Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.

Mechanisms of Broad Cross-Protection Provided by Influenza Virus Infection and Their Application to Vaccines

Influenza M1 VLPs Containing Neuraminidase Induce Heterosubtypic Cross-Protection.

Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Sequential Immunizations with Heterosubtypic Virus-Like Particles Elicit Cross Protection Against Divergent Influenza A Viruses in Mice

Boosting Heterosubtypic Neutralization Antibodies in Recipients of 2009 Pandemic H1N1 Influenza Vaccine

Development of inactivated subunit influenza vaccine endowing with IgA induction and protection against heterologous strain

Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge

Induction of protective immune response to intranasal administration of influenza virus‐like particles in a mouse model

Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7n9 Virus Infection in Humans

Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection

A recombinant protein containing influenza viral conserved epitopes and superantigen induces broad-spectrum protection

Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection

Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus

A vaccine platform targeting lung-resident memory CD4 + T-cells provides protection against heterosubtypic influenza infections in mice and ferrets

Sequential Immunization with Consensus Influenza Hemagglutinins Raises Cross-Reactive Neutralizing Antibodies Against Various Heterologous HA Strains.

Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine

Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity